新天藥業(002873.SZ):擬註銷全資子公司寧波醫藥
格隆匯10月21日丨新天藥業(002873.SZ)公佈,公司於2021年10月21日召開第六屆董事會第二十六次會議,審議通過了《關於實施公司品牌戰略暨註銷寧波全資子公司的議案》,基於公司整體經營規劃和品牌戰略佈局,經過公司審慎研究,決定註銷設立於浙江省寧波市的全資子公司泰和新天(寧波)醫藥有限公司(“寧波醫藥”),並授權公司管理層依法辦理相關注銷事宜。
公吿顯示,基於公司整體經營規劃和品牌戰略佈局,為降低公司管理成本,提高整體經營效率,強化品牌建設,並進一步整合、優化公司資源配置和管理架構,切實有效實施公司品牌戰略規劃,提升公司綜合實力及核心競爭力。經公司審慎研究,決定註銷全資子公司寧波醫藥,並授權公司管理層依法辦理相關注銷事宜。註銷完成後,寧波醫藥將不再納入公司合併財務報表範圍,其原有銷售業務將全部轉入公司本部。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.